Jiangsu Sihuan Bioengineering Co Ltd
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers delusheng and xindelusheng, an anti-tumor biotherapeutic drug for the treatment of kidney cancer, malignant melanoma, and cancerous chest and abdominal mass. It also engages in breeding and sales of flowers and seedlings; and landscaping projects. Jiangsu Sihuan Bioengineering Co., Ltd. was founded … Read more
Market Cap & Net Worth: Jiangsu Sihuan Bioengineering Co Ltd (000518)
Jiangsu Sihuan Bioengineering Co Ltd (SHE:000518) has a market capitalization of $430.78 Million (CN¥3.16 Billion) as of March 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #13762 globally and #3573 in its home market, demonstrating a 6.60% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangsu Sihuan Bioengineering Co Ltd's stock price CN¥3.07 by its total outstanding shares 1029556222 (1.03 Billion).
Jiangsu Sihuan Bioengineering Co Ltd Market Cap History: 2015 to 2026
Jiangsu Sihuan Bioengineering Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $996.27 Million to $430.78 Million (-6.60% CAGR).
Jiangsu Sihuan Bioengineering Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangsu Sihuan Bioengineering Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.74x
Jiangsu Sihuan Bioengineering Co Ltd's market cap is 1.74 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $996.27 Million | $237.84 Million | -$74.45 Million | 4.19x | N/A |
| 2016 | $1.25 Billion | $327.31 Million | $4.47 Million | 3.81x | 278.57x |
| 2017 | $959.78 Million | $346.05 Million | $7.29 Million | 2.77x | 131.69x |
| 2018 | $485.50 Million | $395.51 Million | -$29.44 Million | 1.23x | N/A |
| 2019 | $509.36 Million | $417.88 Million | $14.33 Million | 1.22x | 35.54x |
| 2020 | $718.43 Million | $505.40 Million | $27.30 Million | 1.42x | 26.32x |
| 2021 | $509.36 Million | $350.96 Million | -$38.27 Million | 1.45x | N/A |
| 2022 | $444.81 Million | $270.15 Million | -$53.28 Million | 1.65x | N/A |
| 2023 | $465.86 Million | $235.42 Million | -$75.27 Million | 1.98x | N/A |
| 2024 | $355.01 Million | $203.52 Million | -$109.99 Million | 1.74x | N/A |
Competitor Companies of 000518 by Market Capitalization
Companies near Jiangsu Sihuan Bioengineering Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Jiangsu Sihuan Bioengineering Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Jiangsu Sihuan Bioengineering Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Jiangsu Sihuan Bioengineering Co Ltd's market cap moved from $996.27 Million to $ 430.78 Million, with a yearly change of -6.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥430.78 Million | +27.39% |
| 2025 | CN¥338.17 Million | -4.74% |
| 2024 | CN¥355.01 Million | -23.80% |
| 2023 | CN¥465.86 Million | +4.73% |
| 2022 | CN¥444.81 Million | -12.67% |
| 2021 | CN¥509.36 Million | -29.10% |
| 2020 | CN¥718.43 Million | +41.05% |
| 2019 | CN¥509.36 Million | +4.91% |
| 2018 | CN¥485.50 Million | -49.42% |
| 2017 | CN¥959.78 Million | -22.97% |
| 2016 | CN¥1.25 Billion | +25.07% |
| 2015 | CN¥996.27 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Jiangsu Sihuan Bioengineering Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $430.78 Million USD |
| MoneyControl | $430.78 Million USD |
| MarketWatch | $430.78 Million USD |
| marketcap.company | $430.78 Million USD |
| Reuters | $430.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.